Akebia Therapeutics (Akebia Therapeutics) Debt-to-Equity : -1.57 (As of Mar. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Akebia Therapeutics Debt-to-Equity?

Akebia Therapeutics's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $5.1 Mil. Akebia Therapeutics's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was $37.8 Mil. Akebia Therapeutics's Total Stockholders Equity for the quarter that ended in Mar. 2024 was $-27.3 Mil. Akebia Therapeutics's debt to equity for the quarter that ended in Mar. 2024 was -1.57.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for Akebia Therapeutics's Debt-to-Equity or its related term are showing as below:

AKBA' s Debt-to-Equity Range Over the Past 10 Years
Min: -5.77 Med: 0.28 Max: 19.08
Current: -1.57

During the past 12 years, the highest Debt-to-Equity Ratio of Akebia Therapeutics was 19.08. The lowest was -5.77. And the median was 0.28.

AKBA's Debt-to-Equity is not ranked
in the Biotechnology industry.
Industry Median: 0.14 vs AKBA: -1.57

Akebia Therapeutics Debt-to-Equity Historical Data

The historical data trend for Akebia Therapeutics's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Akebia Therapeutics Debt-to-Equity Chart

Akebia Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Debt-to-Equity

Get a 7-Day Free Trial

0.27

0.51

1.84

19.08

-1.57

Akebia Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Debt-to-Equity	Get a 7-Day Free Trial															-5.77	-2.19	-1.46	-1.57	-1.57

Competitive Comparison of Akebia Therapeutics's Debt-to-Equity

For the Biotechnology subindustry, Akebia Therapeutics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Akebia Therapeutics's Debt-to-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Akebia Therapeutics's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where Akebia Therapeutics's Debt-to-Equity falls into.

Akebia Therapeutics Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Akebia Therapeutics's Debt to Equity Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(21.991	+	26.13)	/	-30.584
	=	-1.57

Akebia Therapeutics's Debt to Equity Ratio for the quarter that ended in Mar. 2024 is calculated as

Debt to Equity	=	Total Debt			/	Total Stockholders Equity
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Stockholders Equity
	=	(5.071	+	37.781)	/	-27.258
	=	-1.57

Akebia Therapeutics (NAS:AKBA) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

Akebia Therapeutics Debt-to-Equity Related Terms

Thank you for viewing the detailed overview of Akebia Therapeutics's Debt-to-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Akebia Therapeutics (Akebia Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Akebia Therapeutics Inc (NAS:AKBA) » Definitions » Debt-to-Equity

Comparable Companies

Traded in Other Exchanges

AX9:Germany AX9:Germany

Address

245 First Street, Cambridge, MA, USA, 02142

Website

https://www.akebia.com

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes 1) Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease. 2) Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients. 3) HIF-PH inhibitors in preclinical development.

Executives

Ellen Snow	officer: SVP, CFO and Treasurer	C/O PEAR THERAPEUTICS, INC., 200 STATE STREET, 13TH FLOOR, BOSTON MA 02109
Michel Dahan	officer: SVP, Chief Business Officer	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, SUITE 1100, CAMBRIDGE MA 02142
Nicole R. Hadas	officer: SVP, General Counsel, Sec.	20 PILGRAM DRIVE, WINCHESTER MA 01890
David A Spellman	officer: SVP, CFO and Treasurer	840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Steven Keith Burke	officer: SVP, Chief Medical Officer	82 WILLIS ROAD, SUDBURY MA 01776
John P. Butler	director, officer: CEO & President	C/O RELYPSA, INC., 700 SAGINAW DR., REDWOOD CITY CA 94063
Steven C Gilman	director	110 HARTWELL AVENUE, LEXINGTON MA 02421
Violetta Cotreau	officer: SVP, Chief Accounting Officer	245 FIRST STREET, 14TH FLOOR, CAMBRIDGE MA 02142
Ron Frieson	director	245 FIRST STREET, 14TH FLOOR, CAMBRIDGE MA 02142
Dell Faulkingham	officer: CCO	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Leanne M Zumwalt	director	C/O THE ADVISORY BOARD CO WATERGATGE, 600 NEW HAMPSHIRE AVE NW, WASHINGTON DC 20037
Maxine Gowen	director
Cynthia Smith	director	508 WRANGLER DRIVE, SUITE 100, COPPELL TX 75019
Myles Wolf	director	C/O AKEBIA THERAPEUTICS, INC., 245 FIRST STREET, CAMBRIDGE MA 02142
Karen L Tubridy	officer: SVP, Chief Development Officer	ELEVEN BIOTHERAPEUTICS, INC., 215 FIRST STREET, SUITE 400, CAMBRIDGE MA 02142